Phase II study of concomitant fluorouracil, hydroxyurea, cetuximab and hyperfractionated intensity modulated radiation therapy for locally advanced head and neck cancer
Latest Information Update: 15 Mar 2018
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Hydroxycarbamide (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 12 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 12 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jul 2007 New trial record.